Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 11, 2011

NEPHROS, INC.
(Exact name of registrant as specified in its charter)


Delaware
 (State or other jurisdiction of incorporation)
 
 
001-32288
 
13-3971809
 
                      
(Commission File Number)
 
(IRS Employer ID Number)
 
         
 
41 Grand Avenue, River Edge, New Jersey
 
07661
 
 
 (Address of principal executive offices)
 
(Zip Code)
 

 
Registrant's telephone number, including area code (201) 343-5202



 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

 
 
Item 8.01.  Other Events.

On August 11, 2011, Nephros, Inc. issued a press release announcing that it filed a 510(k) application with the Food and Drug Administration for clearance of its hemodiafiltration system.  A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.
 
 
(d)           Exhibits
     
 
Exhibit No.
Description
     
 
99.1  
Press release dated August 11, 2011.
 
 
 

 
 

 
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

        
   
Nephros, Inc.
 
       
 
By:
/s/ Gerald J. Kochanski
 
Dated:  August 11, 2011
 
Gerald J. Kochanski
 
   
Chief Financial Officer